Copyright
©The Author(s) 2021.
World J Diabetes. Nov 15, 2021; 12(11): 1875-1893
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1875
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1875
Control (n = 6) | AGEs-20 (n = 6) | AGEs-40 (n = 6) | AGEs-60 (n = 6) | |
MT (mm) | 45.83 ± 3.54 | 57.17 ± 3.25a | 74.83 ± 4.62a | 79.33 ± 3.08a |
LD (mm) | 737.5 ± 9.89 | 769.83 ± 15.73a | 862.33 ± 21.99a | 857.67 ± 15.06a |
MT/LD (%) | 6.21 ± 0.41 | 7.42 ± 0.35a | 8.67 ± 0.37a | 9.25 ± 0.34a |
MA (mm2) | 0.53 ± 0.01 | 0.54 ± 0.01a | 0.55 ± 0.01a | 0.56 ± 0.01a |
LA (mm2) | 1.97 ± 0.04 | 1.85 ± 0.04a | 1.67 ± 0.04a | 1.64 ± 0.04a |
MA/LA (%) | 26.97 ± 0.38 | 29.16 ± 0.73a | 32.99 ± 0.79a | 34.13 ± 0.62a |
SML (layer) | 6.17 ± 0.75 | 7.17 ± 0.73 | 7.67 ± 0.82b | 8.17 ± 0.75b |
- Citation: Xiao ZL, Ma LP, Yang DF, Yang M, Li ZY, Chen MF. Profilin-1 is involved in macroangiopathy induced by advanced glycation end products via vascular remodeling and inflammation. World J Diabetes 2021; 12(11): 1875-1893
- URL: https://www.wjgnet.com/1948-9358/full/v12/i11/1875.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i11.1875